Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.
Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<
Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen.
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.